Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUTERA INCCUTR · Entity 82936 | Director · Chief Executive Officer | February 07, 2025 | February 21, 2025 |
| ESTABLISHMENT LABS HOLDINGS INC.ESTA · Entity 4473 | Director | June 24, 2026 | July 01, 2026 |
| Hyperfine, Inc.HCAQ · Entity 6865 | Director | January 26, 2021 | January 27, 2021 |
| PROCEPT BioRobotics CorpPRCT · Entity 4831 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUTERA INC
Report date February 07, 2025 · Filed February 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 255,744 |
Reported balance
After 2025-02-07 transaction · row 1
1 source rowRow 1 · 2025-02-07 · Tax withholding · Disposed 4,620 · Balance 255,744 F1: Represents the total number of shares withheld by the Company to settle the Reporting Person's tax liability for 15,583 Restricted Stock Units vesting on February 7, 2025. Such withholding is required by the Company's 2019 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the total number of shares withheld by the Company to settle the Reporting Person's tax liability for 15,583 Restricted Stock Units vesting on February 7, 2025. Such withholding is required by the Company's 2019 Equity Incentive Plan.
ESTABLISHMENT LABS HOLDINGS INC.
Report date June 24, 2026 · Filed July 01, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 1,949 |
Reported balance
After 2026-06-24 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 1,949 · Balance 1,949 F1: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest as to 1/3 of the shares subject to the initial award on the yearly anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date. |
| Common SharesSEC Table I · non-derivative | Direct | 3,230 |
Reported balance
After 2026-06-24 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-06-24 · Grant · Acquired 1,773 · Balance 3,230 F2: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest in full on the earlier of June 24, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest as to 1/3 of the shares subject to the initial award on the yearly anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.
F2: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest in full on the earlier of June 24, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date.
Hyperfine, Inc.
Report date January 26, 2021 · Filed January 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-01-26 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-252002) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-252002) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
PROCEPT BioRobotics Corp
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,491 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 3,315 · Balance 102,491 F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.78 · Expires 2036-06-08 | Direct | 5,853 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 5,853 · Balance 5,853 F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MyoKardia, Inc.
Report date November 17, 2020 · Filed November 19, 2020
Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 1
1 source rowRow 1 · 2020-11-17 · Other · Disposed 42,559 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.50 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-17 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.11 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-17 · Disposition to issuer · Disposed 49,400 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.40 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-17 · Disposition to issuer · Disposed 46,060 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Zeltiq Aesthetics Inc
Report date April 28, 2017 · Filed April 28, 2017
Section 16 reporting ended · disclosed 2017-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 1
1 source rowRow 1 · 2017-04-28 · Disposition to issuer · Disposed 62,705 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 62,705 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.81 · Expires 2026-02-01 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-04-28 · Disposition to issuer · Disposed 106,411 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares underlying this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.89 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-04-28 · Disposition to issuer · Disposed 22,232 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares underlying this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 62,705 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares underlying this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 05, 2019 Filed Apr 9, 2019 18:19 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-010398 · doc4.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:21 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-003278 · doc4.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:21 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 49,400 | $0.00 Strike: $40.11 | $0.00 |
DisclosureSEC source: 0000899243-19-003278 · doc4.xml · derivative · entry 1 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,400 Underlying: Common Stock · 49,400 shares Expires 2029-02-07 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2019, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| April 04, 2018 Filed Apr 5, 2018 19:40 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009603 · doc4.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The units vest in equal annual installments over 4 years from April 4, 2018, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The units vest in equal annual installments over 4 years from April 4, 2018, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The units vest in equal annual installments over 4 years from April 4, 2018, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| April 04, 2018 Filed Apr 5, 2018 19:40 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $48.50 | $0.00 |
DisclosureSEC source: 0000899243-18-009603 · doc4.xml · derivative · entry 1 Harris Taylor C. · CIK 0001560168 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-04-03 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable as to 25% of the shares on April 4, 2019, and as to the remainder of the shares in 36 equal monthly installments thereafter, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 13:39 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | Disposition to issuerStock Option (right to buy) · Derivative | 22,232 | $0.00 Strike: $40.89 | $0.00 |
DisclosureSEC source: 0001209191-17-028612 · doc4.xml · derivative · entry 3 Harris Taylor C. · CIK 0001560168 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,232 shares Expires 2027-01-17 F2 · derivative.exercise_date: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares underlying this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 13:39 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | Disposition to issuerStock Option (right to buy) · Derivative | 106,411 | $0.00 Strike: $20.81 | $0.00 |
DisclosureSEC source: 0001209191-17-028612 · doc4.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,411 shares Expires 2026-02-01 F2 · derivative.exercise_date: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares underlying this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 13:39 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | Disposition to issuerCommon Stock | 62,705 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-028612 · doc4.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 62,705 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 62,705 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 11:23 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | Tax withholdingCommon Stock | 5,307 | $55.48 | $294,432.36 |
DisclosureSEC source: 0001209191-17-017051 · doc4.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,705 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 1, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2016 for 55,865 shares. The RSUs vest in four equal annual installments beginning on the first anniversary of March 1, 2016. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 20:15 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | GrantStock Option (right to buy) · Derivative | 22,232 | $0.00 Strike: $40.89 | $0.00 |
DisclosureSEC source: 0001209191-17-005000 · doc4.xml · derivative · entry 2 Harris Taylor C. · CIK 0001560168 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,232 Underlying: Common Stock · 22,232 shares Expires 2027-01-17 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option vest on January 18, 2018, and the remainder vest in equal monthly installments over a 36-month period thereafter, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 20:15 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | GrantCommon Stock | 11,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-005000 · doc4.xml · nonDerivative · entry 1 Harris Taylor C. · CIK 0001560168 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,012 F1 · security: Represents grant of restricted stock units payable solely in common stock that vest in four equal annual installments, with the vesting commencement date of January 18, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.